Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results   tags : Phase 3    save search
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial asses...
Published: 2022-07-14 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K twitter stocktwits trandingview |
Health Technology
 | | O: -1.46% H: 0.09% C: 0.09%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
 | | O: -1.27% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K twitter stocktwits trandingview |
Health Technology
 | | O: -1.0% H: 1.64% C: 0.48%
dupixent children trial positive results sanofi phase 3
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K twitter stocktwits trandingview |
Health Technology
 | | O: -1.46% H: 0.09% C: 0.09%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
 | | O: -1.27% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K twitter stocktwits trandingview |
Health Technology
 | | O: -1.0% H: 1.64% C: 0.48%
dupixent children trial positive results phase 3
Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (SB206) in Patients with Molluscum Contagiosum in JAMA Dermatology
Published: 2022-07-13 (Crawled : 16:00) - prnewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M twitter stocktwits trandingview |
Health Technology
 | | O: -2.0% H: 22.45% C: 4.08%
sb206 molluscum positive results publication study phase 3
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
 | | O: 1.85% H: 1.45% C: 0.66%
VERU | $1.305 -8.1% -8.81% 2.6M twitter stocktwits trandingview |
Health Technology
 | | O: 0.26% H: 20.43% C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Published: 2022-06-30 (Crawled : 01:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.51% H: 0.0% C: 0.0%
takhzyro children trial positive results phase 3
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Published: 2022-06-28 (Crawled : 12:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K twitter stocktwits trandingview |
Health Technology
 | | O: -0.78% H: 1.49% C: -0.15%
trial results sclerosis phase 3 topline
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Published: 2022-06-28 (Crawled : 12:00) - prnewswire.com
JAZZ | $109.96 0.63% 0.63% 760K twitter stocktwits trandingview |
Health Technology
 | | O: -0.78% H: 1.49% C: -0.15%
trial results sclerosis phase 3 topline
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
Published: 2022-06-13 (Crawled : 12:20) - biospace.com/
OPTN | $0.8951 -3.51% -3.64% 650K twitter stocktwits trandingview |
Health Services
 | | O: 17.49% H: 31.63% C: 21.4%
treatment trial positive topline phase 3
Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
Published: 2022-06-08 (Crawled : 12:20) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
 | | O: 3.02% H: 0.98% C: 0.34%
RIGL | $1.07 1.91% 1.87% 810K twitter stocktwits trandingview |
Health Technology
 | | O: -45.22% H: 9.28% C: -21.07%
anemia trial results topline phase 3
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
Published: 2022-06-07 (Crawled : 21:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K twitter stocktwits trandingview |
Health Technology
 | | O: -1.25% H: 0.0% C: 0.0%
conference disease eye trial therapeutics results topline phase 3
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
Published: 2022-06-07 (Crawled : 21:00) - globenewswire.com
DBVT | $0.671 1.51% 1.49% 39K twitter stocktwits trandingview |
Health Technology
 | | O: 19.61% H: 0.0% C: 0.0%
topline trial positive results phase 3
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Published: 2022-06-06 (Crawled : 12:20) - biospace.com/
ARQT | $9.09 -3.81% -3.96% 4.5M twitter stocktwits trandingview |
Health Technology
 | | O: 4.65% H: 1.24% C: -4.42%
topline dermatitis trial positive results phase 3
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
cs-02 trodelvy sciences positive results cancer breast cancer phase 3 her2- her2 metastatic breast cancer
Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Published: 2022-06-03 (Crawled : 14:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320 twitter stocktwits trandingview |
Communications
 | | O: -2.68% H: 0.0% C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M twitter stocktwits trandingview |
Health Technology
 | | O: -0.37% H: 0.0% C: 0.0%
imbruvica risk disease results order phase 3
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
Published: 2022-06-03 (Crawled : 11:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K twitter stocktwits trandingview |
Health Technology
 | | O: 0.11% H: 2.24% C: 1.03%
results phase 3
AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
Published: 2022-06-01 (Crawled : 15:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
 | | O: -0.55% H: 0.0% C: 0.0%
rinvoq trials positive results phase 3
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
 | | O: -1.98% H: 0.0% C: 0.0%
skyrizi disease lancet risankizumab results phase 3
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
 | | O: -1.98% H: 0.0% C: 0.0%
rinvoq lancet results phase 3 ulcerative colitis
SIGMA LITHIUM ANNOUNCES FILING TECHNICAL REPORT WITH OUTSTANDING ECONOMIC RESULTS OF THE INTEGRATED PHASE 1 & 2 PROJECTED PRODUCTION: AFTER-TAX NPV OF US$5.1 BILLION & AVERAGE ANNUAL FREE CASH FLOW OF US$595 MILLION; CONTINUES EVALUATING PHASE 3
Published: 2022-05-26 (Crawled : 14:00) - prnewswire.com
SGML | $13.36 -0.37% -0.37% 670K twitter stocktwits trandingview |
Mining, Quarrying, and Oil and ...
 | | O: 1.17% H: 13.13% C: 10.06%
LTUM | News | $0.0364 33.16% 230K twitter stocktwits trandingview |
Mining, Quarrying, and Oil and ...
 | | O: 0.88% H: 3.54% C: 3.46%
report lithium flow results phase 1 phase 3
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
 | | O: 1.04% H: 1.53% C: 1.37%
ALNY | $144.315 -0.58% -0.59% 700K twitter stocktwits trandingview |
Health Technology
 | | O: -3.53% H: 0.0% C: -1.2%
results phase 3
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance
EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services
NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services
INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.